US Edition
News about Diabetes
Stay current with all the latest and breaking news about Diabetes, compare headlines and perspectives between news sources on stories happening today. In total, 1,640 stories have been published about Diabetes which Ground News has aggregated in the past 3 months.
Local News Publishers
Suggest a source
Looking for a source we don't already have? Suggest one here.Top Diabetes News
Diabetes · DenmarkWegovy Woes: Novo Nordisk Faces Profit Slump Amid Fierce Competition Novo Nordisk, the maker of the obesity drug Wegovy, announced a potential drop in profits and sales by up to 13% this year. This marks the first time in years the company has faced such declines, primarily due to competitive pressures and pricing interventions by former U.S. President Donald Trump.The Danish company's growth, which had seen double-digit increases since Wegovy's…See the Story
Wegovy Woes: Novo Nordisk Faces Profit Slump Amid Fierce Competition
43% Center coverage: 14 sources
Diabetes · ChinaAstraZeneca’s deal with CSPC Pharmaceutical Group includes a Phase 1-ready obesity drug that hits the same targets as Eli Lilly’s obesity drug Zepbound, but with monthly dosing. The new collaboration builds on an existing drug R&D relationship between the two companies. The post AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds appeared first on MedCity News.See the Story
AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds
71% Center coverage: 7 sources
DiabetesNovo Nordisk A/S (NYSE:NVO) on Monday shared headline results from the REIMAGINE 2 phase 3 trial from the global REIMAGINE clinical trial program. CagriSema for weight management was submitted to the U.S. Food and Drug Administration (FDA) in December 2025 based on the REDEFINE 1 and REDEFINE 2 pivotal trials. Trial Data REIMAGINE 2 was a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination…See the Story
Novo Nordisk's Next-Gen Combination Drug Beats Semaglutide in Weight Loss and Blood Sugar Control - Novo Nordisk (NYSE:NVO)
80% Center coverage: 5 sources
